Business Context and Reporting Period
This Form 8-K Current Report was filed by AnaptysBio, Inc. on November 26, 2025. The report discloses significant legal developments regarding a Collaboration and Exclusive License Agreement with TESARO, Inc. and its parent company, GlaxoSmithKline (GSK).
Financial Metrics
This filing is a current report regarding legal proceedings and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Legal Proceedings
- AnaptysBio Lawsuit: On November 20, 2025, AnaptysBio filed a Verified Complaint in Delaware Chancery Court. The complaint alleges that TESARO materially breached the Collaboration Agreement and that GSK tortiously interfered with the agreement. AnaptysBio is seeking a court declaration of its rights and remedies.
- Counter-Lawsuit: On November 26, 2025, TESARO and GSK publicly filed a complaint against AnaptysBio, alleging that AnaptysBio breached the Collaboration Agreement.
- Public Filing: The AnaptysBio Complaint was made publicly available on November 26, 2025, and is included as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors beyond the disclosed litigation. The primary risk identified is the ongoing legal dispute which could impact the Collaboration Agreement and the company's rights thereto. The information in Item 7.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the full text of the AnaptysBio Complaint (Exhibit 99.1) to understand the specific alleged breaches by TESARO.
- Review the counter-complaint filed by TESARO and GSK to assess the allegations against AnaptysBio.
- Monitor the status of the Delaware Chancery Court cases (C.A. No. 2025-1357-KSJM and related filings) for potential injunctions or settlements.
- Assess the potential financial impact of losing rights under the Collaboration Agreement, as no financial data is provided in this specific filing.